Form 4: Avadel Pharmaceuticals Acquired by Alkermes
Acquisition Transaction Report
Avadel Pharmaceuticals plc shareholders receive $21.00 cash and a $1.50 CVR per share as Alkermes plc completes its acquisition.
Summary
- Avadel Pharmaceuticals plc (AVDL) has been acquired by Alkermes plc (Parent) through a scheme of arrangement under Irish law.
- The transaction, contemplated by an agreement dated October 22, 2025, and amended November 18, 2025, became effective on February 12, 2026.
- Each outstanding Ordinary Share of Avadel Pharmaceuticals plc was converted into $21.00 in cash (Cash Consideration) and a non-transferable contingent value right (CVR) entitling holders to a potential additional cash payment of $1.50 per share.
- Restricted Stock Awards outstanding immediately prior to the effective time vested in full and were treated in the same manner as Ordinary Shares.
- Outstanding stock options were canceled and exchanged for cash, equal to the product of the number of shares subject to the option multiplied by the excess of the Cash Consideration ($21.00) over the option's exercise price, plus one CVR for each share subject to the option.
- Linda Palczuk, a Director of Avadel Pharmaceuticals plc, disposed of 78,905 Ordinary Shares and various stock options as a result of this acquisition, holding 0 shares and 0 derivative securities post-transaction.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a positive development for Avadel shareholders, who received a significant cash payout and potential upside through a CVR, indicating a successful exit for the company.
Positives
- Shareholders of Avadel Pharmaceuticals plc received a significant cash consideration of $21.00 per share.
- Shareholders also received a Contingent Value Right (CVR) for a potential additional $1.50 per share, offering further upside.
- Restricted Stock Awards vested fully, allowing holders to participate in the acquisition benefits.
Negatives
- Avadel Pharmaceuticals plc ceases to exist as an independent publicly traded entity.
- The reporting person, Linda Palczuk, no longer holds any direct or indirect beneficial ownership in Avadel Pharmaceuticals plc.
Risks
- The additional $1.50 per share from the Contingent Value Right (CVR) is contingent upon the achievement of certain milestones, meaning this payment is not guaranteed.
Future Outlook
The future outlook for former Avadel Pharmaceuticals plc shareholders includes the potential to receive an additional $1.50 per share via a Contingent Value Right, which is dependent on the achievement of specific, undisclosed milestones.
Industry Context
StockSavvy.ai notes this acquisition aligns with ongoing consolidation and strategic portfolio adjustments within the pharmaceutical sector, where larger entities often acquire smaller, specialized firms for pipeline assets or market access. This transaction represents a strategic move by Alkermes plc to potentially enhance its market position or product offerings.
Comparison to Industry Standards
- StockSavvy.ai notes that cash-plus-CVR deal structures are common in the biotech and pharmaceutical industries, particularly when there is uncertainty regarding the future value of pipeline assets or specific product milestones. Such structures are often employed to bridge valuation gaps between buyer and seller expectations.
- While specific comparable companies or projects are not detailed in this Form 4, the structure allows for immediate value realization for shareholders while retaining potential upside tied to future performance, a mechanism frequently observed in M&A within the life sciences sector.
Stakeholder Impact
- Shareholders of Avadel Pharmaceuticals plc received $21.00 in cash and a Contingent Value Right (CVR) for a potential additional $1.50 per share, representing a favorable outcome for their investment.
- Holders of Restricted Stock Awards and Stock Options also benefited from the acquisition, with their holdings converting to cash and CVRs.
Next Steps
- Achievement of the specific milestones required for the Contingent Value Right (CVR) payment of $1.50 per share.
Key Dates
| Date | Description |
|---|---|
| 10/22/2025 | Date of the original Transaction Agreement between Issuer and Alkermes plc. |
| 11/18/2025 | Date of Amendment No. 1 to the Transaction Agreement. |
| 02/12/2026 | Transaction Date and Effective Time of the Scheme of Arrangement, when the acquisition was consummated. |
| 08/07/2029 | Expiration date for a disposed stock option with an exercise price of $2.03. |
| 08/07/2030 | Expiration date for a disposed stock option with an exercise price of $8.48. |
| 08/03/2031 | Expiration date for a disposed stock option with an exercise price of $8.07. |
| 08/03/2032 | Expiration date for a disposed stock option with an exercise price of $4.79. |
| 08/01/2033 | Expiration date for a disposed stock option with an exercise price of $14.10. |
| 07/30/2034 | Expiration date for a disposed stock option with an exercise price of $16.32. |
| 12/17/2034 | Expiration date for a disposed stock option with an exercise price of $10.93. |
| 07/29/2035 | Expiration date for a disposed stock option with an exercise price of $10.83. |
Recommendation
sellThe company, Avadel Pharmaceuticals plc, has been acquired by Alkermes plc. Shareholders received a fixed cash payment and a contingent value right, meaning their equity in Avadel has been converted, and there are no longer Avadel shares to hold or trade. The transaction is complete, so any remaining Avadel shares would have been converted.
Keywords
Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, Contingent Value Right, CVR, Pharmaceuticals, Biotech, Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.